HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS WITH POLYNEUROPATHY

Clinical trials for HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS WITH POLYNEUROPATHY explained in plain language.

Never miss a new study

Get alerted when new HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS WITH POLYNEUROPATHY trials appear

Sign up with your email to follow new studies for HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS WITH POLYNEUROPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New drug trial aims to halt rare, debilitating nerve disease

Disease control Recruiting now

This study is testing an investigational drug called nucresiran for people with hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN), a rare disease that causes progressive nerve damage. The goal is to see if nucresiran can slow or stop the worsening of nerve funct…

Matched conditions: HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS WITH POLYNEUROPATHY

Phase: PHASE3 • Sponsor: Alnylam Pharmaceuticals • Aim: Disease control

Last updated Mar 20, 2026 14:47 UTC

HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS WITH POLYNEUROPATHY

Get alerted when new HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS WITH POLYNEUROPATHY trials appear

New drug trial aims to halt rare, debilitating nerve disease